Kakisaka Keisuke, Suzuki Yuji, Jinnouchi Yukina, Kanazawa Jo, Sasaki Tokio, Yonezawa Takehiro, Yoshida Yuichi, Kuroda Hidekatsu, Takikawa Yasuhiro
Division of Hepatology, Department of Internal Medicine, Iwate Medical University, School of Medicine, Iwate, Japan.
Hepatol Res. 2019 Nov;49(11):1286-1293. doi: 10.1111/hepr.13397. Epub 2019 Jul 26.
Acute liver injury (ALI) has a favorable prognosis, whereas acute liver failure (ALF) leads to organ failure and thus has an unfavorable prognosis. The effect of each etiology on the clinical course of ALI remains unclear. This study aimed to determine how each etiology and glucocorticoid on the unfavorable etiology affects the clinical course of ALI.
This prospective observational study enrolled 522 patients with ALI/ALF from 2004 and 2017. To evaluate the influence of etiology on prognosis, decision tree analysis was carried out using age, disease type, etiology, and the presence of hepatic encephalopathy.
Of 522 patients, 398 patients satisfied the ALI criteria at registration in this study. The ALI etiologies were as follows: viral hepatitis through oral infection (n = 54), acute hepatitis B virus (HBV) infection (n = 24), acute exacerbation of HBV infection (n = 30), de novo hepatitis due to HBV (n = 5), autoimmune hepatitis (n = 59), drug-induced liver injury (DILI; n = 85), other viruses (n = 12), and undetermined (n = 129). ALI in 46 patients progressed to ALF after registration. Of 11 patients (age >52 years) with ALF due to acute exacerbation of HBV infection or DILI, seven patients (63.6%) died. Whether glucocorticoid affected the clinical course of ALI due to acute exacerbation of HBV infection or DILI was evaluated using propensity score matching (age, sex, alanine aminotransferase, total bilirubin, and prothrombin time-international normalized ratio). Glucocorticoid did not improve the prognosis of ALI patients due to the two etiologies.
Progression of ALI due to DILI or acute exacerbation of HBV infection to ALF showed a poor prognosis.
急性肝损伤(ALI)预后良好,而急性肝衰竭(ALF)会导致器官衰竭,因此预后不良。每种病因对ALI临床病程的影响尚不清楚。本研究旨在确定每种病因以及糖皮质激素对不良病因如何影响ALI的临床病程。
这项前瞻性观察性研究纳入了2004年至2017年期间的522例ALI/ALF患者。为评估病因对预后的影响,使用年龄、疾病类型、病因和肝性脑病的存在情况进行决策树分析。
在522例患者中,398例患者在本研究登记时符合ALI标准。ALI的病因如下:经口感染的病毒性肝炎(n = 54)、急性乙型肝炎病毒(HBV)感染(n = 24)、HBV感染急性加重(n = 30)、HBV所致新发肝炎(n = 5)、自身免疫性肝炎(n = 59)、药物性肝损伤(DILI;n = 85)、其他病毒(n = 12)和病因未明(n = 129)。46例患者的ALI在登记后进展为ALF。在11例因HBV感染急性加重或DILI导致ALF的患者(年龄>52岁)中,7例患者(63.6%)死亡。使用倾向评分匹配(年龄、性别、丙氨酸转氨酶、总胆红素和凝血酶原时间-国际标准化比值)评估糖皮质激素是否影响因HBV感染急性加重或DILI导致的ALI的临床病程。糖皮质激素并未改善这两种病因所致ALI患者的预后。
因DILI或HBV感染急性加重导致的ALI进展为ALF时预后较差。